BR112018010806A2 - 1,3,4-thiadiazole compounds and their use in cancer treatment - Google Patents

1,3,4-thiadiazole compounds and their use in cancer treatment

Info

Publication number
BR112018010806A2
BR112018010806A2 BR112018010806-5A BR112018010806A BR112018010806A2 BR 112018010806 A2 BR112018010806 A2 BR 112018010806A2 BR 112018010806 A BR112018010806 A BR 112018010806A BR 112018010806 A2 BR112018010806 A2 BR 112018010806A2
Authority
BR
Brazil
Prior art keywords
methoxy
phenyl
thiadiazol
amino
acetamide
Prior art date
Application number
BR112018010806-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Raymond Verschoyle Finlay Maurice
Wilhelmus Maria Nissink Johannes
David Charles Mark
Original Assignee
Astrazeneca Ab
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Technology Limited filed Critical Astrazeneca Ab
Publication of BR112018010806A2 publication Critical patent/BR112018010806A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018010806-5A 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in cancer treatment BR112018010806A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
US62/260,789 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
BR112018010806A2 true BR112018010806A2 (en) 2018-11-27

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010806-5A BR112018010806A2 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in cancer treatment

Country Status (24)

Country Link
US (3) US10323028B2 (cg-RX-API-DMAC7.html)
EP (1) EP3383873B1 (cg-RX-API-DMAC7.html)
JP (1) JP6999550B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180083942A (cg-RX-API-DMAC7.html)
CN (1) CN108349966B (cg-RX-API-DMAC7.html)
AR (1) AR106874A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016363718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018010806A2 (cg-RX-API-DMAC7.html)
CA (1) CA3005495C (cg-RX-API-DMAC7.html)
CL (1) CL2018001407A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018006928A2 (cg-RX-API-DMAC7.html)
EA (1) EA201891241A1 (cg-RX-API-DMAC7.html)
ES (1) ES2914333T3 (cg-RX-API-DMAC7.html)
IL (1) IL259510A (cg-RX-API-DMAC7.html)
MX (1) MX2018006532A (cg-RX-API-DMAC7.html)
NI (1) NI201800064A (cg-RX-API-DMAC7.html)
PE (1) PE20181565A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501131A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018123714A (cg-RX-API-DMAC7.html)
SG (1) SG11201803810XA (cg-RX-API-DMAC7.html)
SV (1) SV2018005702A (cg-RX-API-DMAC7.html)
TN (1) TN2018000127A1 (cg-RX-API-DMAC7.html)
TW (1) TW201733587A (cg-RX-API-DMAC7.html)
WO (1) WO2017093299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN110741003B (zh) * 2017-06-13 2021-07-23 南京明德新药研发有限公司 作为gls1抑制剂的化合物
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
HUE056078T2 (hu) * 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
US11753405B2 (en) 2023-09-12
SG11201803810XA (en) 2018-06-28
CL2018001407A1 (es) 2018-10-12
MX2018006532A (es) 2019-05-15
US20170152255A1 (en) 2017-06-01
JP2018535986A (ja) 2018-12-06
PE20181565A1 (es) 2018-10-03
WO2017093299A1 (en) 2017-06-08
CN108349966A (zh) 2018-07-31
CA3005495A1 (en) 2017-06-08
EP3383873A1 (en) 2018-10-10
AU2016363718B2 (en) 2019-11-14
CA3005495C (en) 2023-12-12
SV2018005702A (es) 2018-11-27
US10323028B2 (en) 2019-06-18
PH12018501131A1 (en) 2019-01-21
AU2016363718A1 (en) 2018-07-12
US20210246131A1 (en) 2021-08-12
CN108349966B (zh) 2022-02-15
NI201800064A (es) 2018-10-18
JP6999550B2 (ja) 2022-02-10
ES2914333T3 (es) 2022-06-09
TN2018000127A1 (en) 2019-10-04
TW201733587A (zh) 2017-10-01
RU2018123714A (ru) 2020-01-09
US10981904B2 (en) 2021-04-20
IL259510A (en) 2018-07-31
CO2018006928A2 (es) 2018-10-10
EA201891241A1 (ru) 2019-01-31
KR20180083942A (ko) 2018-07-23
AR106874A1 (es) 2018-02-28
US20190389853A1 (en) 2019-12-26
EP3383873B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
EA201891241A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
JOP20200209A1 (ar) مثبطات cd73
MX389450B (es) Compuesto novedoso de pirimidina condensada o sal del mismo.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2018003351A (es) Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer.
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
BR112018010812A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
BR112018008330A2 (pt) compostos 1,3,4-tiadiazol e seu uso no tratamento de câncer
AR100694A1 (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
CO2022000270A2 (es) Inhibidores de enzimas
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
PH12021550374A1 (en) Small molecule menin inhibitors
BR112018067552A2 (pt) inibidores de cinase
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
MX389613B (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
BR112018016554A2 (pt) composto de uréia, método de preparação deste e uso médico deste
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
PL428024A1 (pl) Sulfonowana pochodna polistyrenu do zastosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez kociego herpeswirusa

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]